Agonist antibody to MuSK protects mice from MuSK myasthenia gravis
Open Access
- 17 September 2024
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (39)
Abstract
Myasthenia gravis (MG) is a chronic and severe disease of the skeletal neuromuscular junction (NMJ) in which the effects of neurotransmitters are attenuated, leading to muscle weakness. In the most common forms of autoimmune MG, antibodies attack components of the postsynaptic membrane, including the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). MuSK, a master regulator of NMJ development, associates with the low-density lipoprotein-related receptor 4 (Lrp4) to form the signaling receptor for neuronal Agrin, a nerve-derived synaptic organizer. Pathogenic antibodies to MuSK interfere with binding between MuSK and Lrp4, inhibiting the differentiation and maintenance of the NMJ. MuSK MG can be debilitating and refractory to treatments that are effective for AChR MG. We show here that recombinant antibodies, derived from MuSK MG patients, cause severe neuromuscular disease in mice. The disease can be prevented by a MuSK agonist antibody, presented either prophylactically or after disease onset. These findings suggest a therapeutic alternative to generalized immunosuppression for treating MuSK MG by selectively and directly targeting the disease mechanism.Keywords
Funding Information
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R37 NS36193)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (1R01AG051490)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (5 U19NS107616)
- Prinses Beatrix Spierfonds (W.OR-19.13)
- Argenx (no number)
This publication has 42 references indexed in Scilit:
- MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilationJournal of Neurology, 2021
- Muscle specific kinase (MuSK) activation preserves neuromuscular junctions in the diaphragm but is not sufficient to provide a functional benefit in the SOD1G93A mouse model of ALSNeurobiology of Disease, 2019
- Antibodies against Wnt receptor of muscle-specific tyrosine kinase in myasthenia gravisJournal of Neuroimmunology, 2013
- Increasing MuSK Activity Delays Denervation and Improves Motor Function in ALS MiceCell Reports, 2012
- Wnt Signals Organize Synaptic Prepattern and Axon Guidance through the Zebrafish unplugged/MuSK ReceptorNeuron, 2009
- LRP4 Serves as a Coreceptor of AgrinNeuron, 2008
- Lrp4 Is a Receptor for Agrin and Forms a Complex with MuSKCell, 2008
- Crystal Structure of the Agrin-responsive Immunoglobulin-like Domains 1 and 2 of the Receptor Tyrosine Kinase MuSKJournal of Molecular Biology, 2006
- Agrin Acts via a MuSK Receptor ComplexCell, 1996
- The Receptor Tyrosine Kinase MuSK Is Required for Neuromuscular Junction Formation In VivoCell, 1996